Qube Research & Technologies (QRT)
KZIA

Qube Research & Technologies (QRT)’s Kazia Therapeutics KZIA Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$78.9K Buy
+10,608
New +$73.8K ﹤0.01% 3108

Other funds holding KZIA

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Qube Research & Technologies (QRT)'s KZIA Position: Q1 2026 in Review

Qube Research & Technologies (QRT) opened a new position in Kazia Therapeutics (KZIA) in Q1 2026: 10,608 shares worth $78.9K. The stake represents ﹤0.01% of the portfolio and ranks #3108 among its holdings.

23 funds tracked by Wall St. Rank hold KZIA as of Q1 2026.

  • Qube Research & Technologies (QRT) held 10,608 shares of Kazia Therapeutics worth $78.9K as of Q1 2026.
  • Kazia Therapeutics was a new Qube Research & Technologies (QRT) position in Q1 2026.
  • Kazia Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #3108 holding.
  • 23 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.